Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) is an American multinational corporation founded in 1886, widely recognized as the world’s largest and most diversified healthcare company. The company is structured into three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products. The pharmaceutical division, which contributes significantly to the company's revenue, focuses on therapeutic areas such as immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The medical devices segment specializes in orthopedics, surgical instruments, and vision care. The consumer health division, known for products in baby care, beauty, oral care, over-the-counter drugs, and women's health, is set to be divested in 2023 under the new name Kenvue.
In recent developments, Johnson & Johnson has made headlines with the expanded approval of CARVYKTI® (ciltacabtagene autoleucel), a one-time infusion therapy for multiple myeloma. This approval is based on the successful Phase 3 CARTITUDE-4 study, showing a significant reduction in disease progression or death by 59% compared to traditional therapies. Such advancements underscore Johnson & Johnson's dedication to innovative treatments, particularly in oncology.
Financially, Johnson & Johnson generates over half of its revenue from the United States, with the pharmaceuticals and medical devices divisions driving the majority of cash flows. The company continues to invest heavily in research and development, aiming to transform healthcare through smarter and less invasive treatments. Their strategic partnerships and focus on emerging markets further cement their position as a leader in the healthcare industry.
With a commitment to improving global health, Johnson & Johnson's innovative solutions span across the full spectrum of healthcare, striving to prevent, treat, and cure complex diseases. For more information, visit their official website at www.jnj.com.
Johnson & Johnson (NYSE: JNJ) announced that the FDA's Vaccines Advisory Committee voted 19-0 in favor of Emergency Use Authorization (EUA) for a booster dose of its COVID-19 vaccine for adults at least two months post-initial vaccination. This decision is backed by results from the Phase 3 ENSEMBLE 2 trial showing 94% protection against symptomatic COVID-19 after two months and 100% against severe cases. The company's commitment to combat COVID-19 continues as it awaits further regulatory decisions both nationally and internationally.
On October 14, 2021, lawyers representing over 30,000 women filed lawsuits against Johnson & Johnson (JNJ) regarding cancer claims tied to its talc body powders. They criticize J&J's bankruptcy move to evade legal accountability as hypocritical and unjust, especially given the company's substantial profits. J&J’s new subsidiary, LTL Management LLC, has filed for bankruptcy to manage these claims, proposing a $2 billion settlement fund despite total liabilities estimated at over $25 billion. The legal battle raises concerns for pending trials and could prolong suffering for affected patients.
Johnson & Johnson (NYSE: JNJ) announced that LTL Management LLC, a newly formed subsidiary, has filed for voluntary Chapter 11 bankruptcy to manage claims related to cosmetic talc litigation. This bankruptcy aims to provide an equitable resolution for current and future claimants. JNJ will fund LTL with a $2 billion trust and royalty revenue streams worth over $350 million. The company maintains its stance on the safety of its talc products, citing favorable jury trial outcomes. All cosmetic talc litigation cases will be stayed pending the bankruptcy proceedings.
Johnson & Johnson (NYSE: JNJ) is set to host a Business Review for the investment community on November 18, 2021. The event will offer insights into the company's Pharmaceuticals business, highlighting its unique strategy and strong pipeline for growth. Participants can expect a detailed overview of six therapeutic areas, live sessions with executives, and Q&A opportunities. Registration opens on November 1. A replay of the event will be available after it concludes.
Johnson & Johnson (NYSE: JNJ) appointed Jessica Moore as Vice President of Investor Relations, effective November 1, 2021. Moore, with 20 years of financial experience, most recently served as CFO for the Janssen Pharmaceutical business in EMEA. She will report to Joseph Wolk, CFO, and is expected to enhance communication of JNJ's strategies to investors. Moore holds degrees in Finance and Accounting and an MBA. This leadership change aims to leverage her expertise to positively impact JNJ's financial narrative.
Johnson & Johnson (NYSE: JNJ) announced the retirement of Dr. Paul Stoffels, Vice Chairman and Chief Scientific Officer, effective December 31, 2021. Dr. Stoffels has been pivotal in enhancing the company's innovation pipeline, leading initiatives that delivered over 25 new medicines, some of which are on the WHO's Essential Medicines List. He also played a key role in developing the COVID-19 vaccine and in global health advocacy. Johnson & Johnson aims to continue his legacy of innovation and public health commitment under new leadership.
Johnson & Johnson (NYSE: JNJ) will participate virtually in the Credit Suisse 30th Annual Healthcare Conference on November 10, 2021. Ashley McEvoy, Executive Vice President and Worldwide Chairman of Medical Devices, will represent the company in a session at 11:20 a.m. ET. This event will be accessible to investors and interested parties via the Johnson & Johnson website. A webcast and podcast replay will be available about 48 hours post-event.
For more details, visit www.investor.jnj.com.
On October 6, 2021, Janssen Pharmaceutical Companies of Johnson & Johnson revealed groundbreaking preclinical data in Nature, showcasing a novel antiviral compound that may treat all dengue fever serotypes. The compound operates by obstructing key viral proteins, inhibiting replication, and demonstrating efficacy in both prevention and treatment settings. As dengue affects up to 400 million people annually, this advancement marks a significant step in addressing a critical public health issue. Janssen aims to escalate the compound's clinical development to deliver impactful solutions for at-risk communities.
Johnson & Johnson (NYSE: JNJ) announced the submission of data to the FDA for a booster shot of its COVID-19 vaccine for individuals aged 18 and older. Results from the Phase 3 ENSEMBLE 2 study show that a booster administered 56 days after the primary dose offers 94% protection against symptomatic COVID-19 and 100% against severe/critical cases. Additionally, Phase 1/2a data indicates a nine-fold increase in antibody levels after a booster at six months. The company plans further submissions to global health authorities to support vaccine administration strategies.
FAQ
What is the current stock price of Johnson & Johnson (JNJ)?
What is the market cap of Johnson & Johnson (JNJ)?
What are the main business segments of Johnson & Johnson?
What recent developments have there been in Johnson & Johnson's pharmaceutical division?
What products are included in Johnson & Johnson’s consumer health segment?
What is CARVYKTI®?
What percentage of Johnson & Johnson's revenue is generated in the United States?
What is the focus of Johnson & Johnson’s medical devices segment?
What changes are happening with Johnson & Johnson’s consumer health division?
How does Johnson & Johnson contribute to global healthcare?
Where can I find more information about Johnson & Johnson?
What therapeutic areas does Johnson & Johnson's pharmaceutical division focus on?
